L-Carnitine

Compound	L-Carnitine (3-hydroxy-4-N-trimethylaminobutyrate)
Chemical class	Quaternary ammonium zwitterion — not a proteinogenic amino acid
CAS	541-15-1 (L-carnitine) · 6645-46-1 (L-carnitine HCl)
Molecular weight	161.20 g/mol
Biosynthesis	From lysine and methionine; requires vitamin C, iron, B6 and niacin
Key applications	Mitochondrial long-chain fatty acid transport, secondary deficiency correction
Claim strength	High for the carnitine shuttle and secondary deficiency; Emerging for weight management
Buy from Herbuno	L-Carnitine L-Tartrate Powder · L-Carnitine Fumarate Powder · free base / HCl: availability on request
Origin	Processed / Sourced from India
MOQ	R&D 100 g / 250 g (subject to stock) · Pilot batch 1–5 kg · Bulk 10 kg, 25 kg and above
Lead Time	Dispatch within 72 hrs from stock · fresh-batch production (typically 50 kg+): 10 working days
Documentation	CoA & MSDS standard with every lot

Name origin: From the Latin carnis, flesh, reflecting its 1905 isolation from muscle extract by Gulewitsch and Krimberg. For decades it was designated vitamin B_T, a name no longer used, after the discovery that the mealworm Tenebrio molitor requires it as a dietary factor. Humans do not: carnitine is synthesised endogenously, which is why it is a conditionally rather than absolutely essential nutrient.

Biochemical position: Carnitine is not an amino acid in the proteinogenic sense — it is a quaternary ammonium compound and a zwitterion at physiological pH, with a permanently charged trimethylammonium group. That permanent charge is the source of both its biological function and its handling difficulty. It is synthesised in liver, kidney and brain from lysine and methionine through a pathway requiring vitamin C, iron, pyridoxine and niacin, so carnitine status is indirectly dependent on those micronutrients.

Research trajectory: Carnitine's established function is the carnitine shuttle, which transports long-chain fatty acids across the inner mitochondrial membrane for β-oxidation. That is settled biochemistry. The supplement literature has largely pursued the inference that supplying more carnitine should increase fat oxidation, which has not held up cleanly, because muscle carnitine concentration is difficult to raise by oral dosing alone. The better-supported clinical applications are in secondary carnitine deficiency — dialysis, valproate therapy, pivalate-conjugated antibiotics — and in specific genetic transport disorders.

Commercial source: L-carnitine is manufactured either by chemoenzymatic synthesis or by fermentation, and the chirality is critical: only the L-enantiomer is active, and D-carnitine is not merely inert but a competitive inhibitor of carnitine transport. Racemic DL-carnitine is therefore unacceptable for human use, which distinguishes carnitine sharply from DL-methionine, where the D-form is usefully converted. Commercially, carnitine moves principally as the tartrate or fumarate salt rather than as the free base.

---

Evidence for L-Carnitine Applications

The carnitine shuttle is settled biochemistry and the only unqualified claim available. Long-chain fatty acids cannot cross the inner mitochondrial membrane as acyl-CoA; carnitine palmitoyltransferase I esterifies them to carnitine on the outer membrane, the acylcarnitine crosses via the carnitine-acylcarnitine translocase, and CPT II regenerates the acyl-CoA inside for β-oxidation. Without carnitine, long-chain fat oxidation does not occur. This is a textbook pathway and genetic defects in its components cause severe metabolic disease. Claim strength: High.

The inference from that pathway to a fat-loss claim does not follow, and this is the central honesty requirement for the ingredient. Carnitine is not rate-limiting for fat oxidation in healthy, carnitine-replete muscle, so adding substrate to a non-limiting step does not increase flux. Meta-analytic work on carnitine and body weight has reported small effects, generally under two kilograms and with substantial heterogeneity, and the mechanism behind those findings is not established. Positioning carnitine as a fat burner overstates a body of evidence that is at best modest. Claim strength: Emerging.

Muscle carnitine concentration is difficult to raise by oral dosing alone, which is the most practically important fact for a formulator. Skeletal muscle holds the large majority of body carnitine, and transport into muscle occurs against a steep concentration gradient via the OCTN2 transporter. Oral carnitine raises plasma concentration but muscle uptake is insulin- dependent, so carnitine taken without a substantial carbohydrate load largely does not reach muscle. Studies achieving muscle carnitine increases have used carnitine with large carbohydrate co-ingestion over weeks. A carnitine product intended to affect muscle should be designed around that constraint rather than ignoring it. Claim strength: Moderate.

Oral bioavailability is low and differs markedly from dietary carnitine, which affects dose design. Dietary carnitine from meat and dairy is absorbed at roughly 54 to 87%, while supplemental carnitine is absorbed at approximately 14 to 18%, with the remainder largely degraded by intestinal microbiota. The difference is attributed to the carrier-mediated absorption being saturated at bolus supplemental doses. Dividing doses improves the position modestly; it does not eliminate the gap. Claim strength: High.

Secondary carnitine deficiency is a real clinical entity and the strongest application for supplementation. It occurs in haemodialysis patients, in long-term valproate therapy, with pivalate-conjugated antibiotics, in some inborn errors of metabolism, and occasionally in severely restricted vegan diets combined with impaired synthesis. In these settings carnitine supplementation corrects a genuine deficit, and intravenous L-carnitine is an approved therapy for dialysis-associated deficiency in several jurisdictions. This is a clinical nutrition application rather than a general wellness one. Claim strength: High.

The TMAO question is a legitimate caveat that should not be omitted from technical documentation. Gut microbiota metabolise carnitine to trimethylamine, which the liver oxidises to trimethylamine N-oxide, and elevated circulating TMAO has been associated with cardiovascular risk in observational cohorts. Whether TMAO is causal, a marker, or a confounded correlate of dietary pattern remains unresolved, and intervention data are absent. The honest position is that the association exists, the causality is unestablished, and a customer formulating long-term high-dose carnitine should be aware of it. Claim strength: Emerging.

---

Dosage & Formulator Specification

Doses in the literature run 500 milligrams to 2 grams of L-carnitine daily for general use, with higher intakes of 2 to 4 grams used in clinical deficiency settings and in some exercise studies. Because carnitine is almost always supplied as a salt, dose on carnitine content rather than salt weight: L-carnitine L-tartrate is approximately 68.2% carnitine, fumarate approximately 58.1%, hydrochloride approximately 81.6%. A 1 gram carnitine target therefore requires about 1.47 grams of tartrate, 1.72 grams of fumarate or 1.23 grams of hydrochloride. Divided dosing partially mitigates the saturable absorption.

Chirality specification is non-negotiable and is the point most worth labouring. In most amino acid categories a D- or DL- form is simply nutritionally diluted; carnitine is different, because D-carnitine competes with L-carnitine for the OCTN2 transporter and for carnitine acyltransferases, so its presence actively opposes the function of the L-form. Historical clinical problems with racemic carnitine, including myasthenic symptoms in dialysis patients, arose from exactly this. Require optical rotation or a chiral method on every certificate, and treat an unexplained price advantage in this category as a reason to test rather than to order.

Hygroscopicity dominates handling and is why the salts exist. Free-base L-carnitine is a zwitterion with a permanently charged quaternary ammonium group and is extremely hygroscopic — it will absorb atmospheric moisture to the point of deliquescence under ordinary warehouse conditions, caking and liquefying in the container. It is workable only in liquids, under tight humidity control, or with specialised packaging. The tartrate and fumarate are free-flowing crystalline powders that behave normally in dry blends, tableting and capsule filling, which is the whole commercial rationale for them.

Formulating for muscle carnitine requires designing around insulin, and most products do not. Muscle uptake via OCTN2 works against a steep gradient and is insulin-stimulated, so carnitine delivered without a substantial carbohydrate load largely stays in plasma and is excreted. The studies that successfully raised muscle carnitine used carnitine alongside large carbohydrate doses, repeated over weeks. For a product whose claim depends on muscle carnitine, either build the carbohydrate in and set the expectation of a multi-week protocol, or make a claim that does not depend on muscle concentration. Stating this plainly is more useful to a formulator than implying a single pre-workout dose achieves it.

For analytical control, specify L-carnitine identity and assay with the basis stated — carnitine content or salt — optical rotation or chiral chromatography confirming L-configuration, counter-ion content confirming salt stoichiometry, and water content, since these materials are moisture-sensitive to varying degrees. Standard coverage includes heavy metals, residual solvents, microbiological limits, loss on drying and sulphated ash. For fermentation-derived material, specify residual host-cell protein and endotoxin and name the organism and substrate; for chemoenzymatic routes, name the relevant process-related impurities and the enzyme source for certification purposes.

On salt selection, the decision is reasonably clear once density and function are separated. The tartrate is the usual default for dry formats: highest carnitine fraction among the common non-hygroscopic salts, free-flowing, and the form used in the recovery and exercise literature specifically identified as LCLT. The fumarate carries less carnitine per gram but supplies fumarate, a tricarboxylic acid cycle intermediate, and is often chosen where that is wanted or where the tartrate's acid profile is unhelpful. The hydrochloride gives the highest carnitine density but introduces chloride and acidity. The free base is for liquids and tightly controlled environments only. Acetyl-L-carnitine is a different proposition altogether, being selected for central rather than peripheral activity.

---

Frequently Asked Questions — L-Carnitine

Related compounds: L-Lysine · L-Methionine · Choline · Betaine · Creatine Monohydrate